DNA RNA and Cells

17 Oct 2017 Incysus Announces FDA Approval of IND Application for a Phase 1 Study of a Gamma-Delta (γδ) T Cell Leukemia and Lymphoma Immunotherapy
16 Oct 2017 ZIOPHARM Oncology Announces First Patient Dosed in New Phase 1 Study of Ad-RTS-hIL-12 plus Veledimex for the Treatment of Pediatric Brain Tumors
16 Oct 2017 BrainStorm Enrolls First Patients in Phase 3 Trial of NurOwn® in ALS
13 Oct 2017 FDA Advisory Committee Unanimously Recommends Approval of Investigational LUXTURNA™ (voretigene neparvovec) for Patients with Biallelic RPE65-mediated Inherited Retinal Disease
13 Oct 2017 miRagen Therapeutics Presents New Clinical Data Suggesting Positive Impact From Systemically Administered MRG-106 on Mycosis Fungoides Form of Cutaneous T-Cell Lymphoma at EORTC Global Task Force Meeting
13 Oct 2017 Ionis Pharmaceuticals Initiates Clinical Study of IONIS-MAPT Rx in Patients with Alzheimer's Disease
11 Oct 2017 Mustang Bio Announces $12.8 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-101 in Malignant Glioma
06 Oct 2017 Capricor Therapeutics Reports Intravenous Administration of CAP-1002 Shown to be Effective in Preclinical Models of Duchenne Muscular Dystrophy
06 Oct 2017 Abeona Announces Top-Line One Year Data from ABO-102 MPS IIIA Trial at ARM’s Cell & Gene Meeting on the Mesa
06 Oct 2017 bluebird bio Announces Publication of Interim Data from Starbeam Study of Lenti-DTM Drug Product in Patients with Cerebral Adrenoleukodystrophy (CALD) in The New England Journal of Medicine
06 Oct 2017 Biogen’s SPINRAZA® (nusinersen) Data Show Earlier Treatment Initiation May Lead to Improved Motor Function Across a Broad Population of People Living with Spinal Muscular Atrophy
06 Oct 2017 First Randomized Study To Evaluate IMLYGIC® (Talimogene Laherparepvec), An Oncolytic Viral Therapy, In Combination With A Checkpoint Inhibitor Published In The Journal Of Clinical Oncology
05 Oct 2017 AVROBIO, Inc. Expands Rare Disease Pipeline with Gene Therapy to Treat Cystinosis
04 Oct 2017 AOBiome Commences Patient Enrollment in Phase 1b/2a Clinical Trial of Ammonia Oxidizing Bacteria (AOB) for the Treatment of Seasonal Allergic Rhinitis
03 Oct 2017 AmpliPhi Biosciences Announces Publication of Preclinical Data for AB-PA01 Showing Activity in Reducing Biofilms of Pseudomonas Aeruginosa
03 Oct 2017 Seres Therapeutics reports positive topline results from SER-287 phase 1b study in patients with ulcerative colitis
03 Oct 2017 VBL Therapeutics Announces Positive Outcome in the Third and Final DSMC Review of Phase 3 GLOBE Trial Investigating VB-111 in Recurrent GBM
03 Oct 2017 Sangamo And Bioverativ Announce FDA Acceptance Of IND Application For ST-400 -- A Gene-Edited Cell Therapy Candidate -- To Treat Beta-Thalassemia
29 Sep 2017 Nohla Therapeutics Awarded $6.9 Million Grant from the California Institute of Regenerative Medicine to Further Develop NLA101 Cell Therapy for the Treatment of Patients with Acute Myeloid Leukemia
29 Sep 2017 bluebird bio Announces First Patient Treated with Second Anti-BCMA CAR T bb21217 in CRB-402 Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma
28 Sep 2017 Genelux Initiates Phase 2 Clinical Trial of GL-ONC1 in Recurrent Ovarian Cancer
28 Sep 2017 Asterias Receives Regulatory Clearance to Initiate Clinical Study of AST-VAC2 in Subjects with Early and Late Stage Non-Small Cell Lung Cancer
28 Sep 2017 Poseida Therapeutics Opens Enrollment in a Phase 1 Study of BCMA-Specific CAR-T Stem Cell Memory Therapy for Patients with Multiple Myeloma
28 Sep 2017 Fibrocell Reports Interim Results of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa
28 Sep 2017 Alnylam Initiates Phase 2 Clinical Study of Cemdisiran (ALN-CC5) in Patients with Atypical Hemolytic-Uremic Syndrome (aHUS)

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top